Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. https://doi.org/10.1093/jnci/85.5.365.
Cankurtaran, E. S., Ozalp, E., Soygur, H., Ozer, S., Akbiyik, D. I., & Bottomley, A. (2008). Understanding the reliability and validity of the EORTC QLQ-C30 in Turkish cancer patients. European Journal Cancer Care (England), 17(1), 98–104. https://doi.org/10.1111/j.1365-2354.2007.00827.x.
Article
CAS
Google Scholar
Cronbach, L. J., & Warrington, W. G. (1951). Time-limit tests: Estimating their reliability and degree of speeding. Psychometrika, 16(2), 167–188. https://doi.org/10.1007/BF02289113.
Article
CAS
PubMed
Google Scholar
Detmar, S. B., Muller, M. J., Schornagel, J. H., Wever, L. D., & Aaronson, N. K. (2002). Health-related quality-of-life assessments and patient-physician communication: A randomized controlled trial. JAMA, 288(23), 3027–3034. https://doi.org/10.1001/jama.288.23.3027.
Article
PubMed
Google Scholar
European Medicines Agency (2016) Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf.
Fallowfield, L. (2002). Quality of life: A new perspective for cancer patients. Nature Reviews. Cancer, 2(11), 873–879. https://doi.org/10.1038/nrc930.
Article
CAS
PubMed
Google Scholar
Fayers, P., Aaronson, N., & Bjordal, K. (1999). EORTC QLQ-C30 scoring manual, (2nd ed.) Brussels: EORTC Quality of Life Study Group.
FDA Center for Drug Evaluation and Research (2009) Patient-reported outcome measures: Use in medical product development. https://www.fda.gov/media/77832/download.
Guzelant, A., Goksel, T., Ozkok, S., Tasbakan, S., Aysan, T., & Bottomley, A. (2004). The European Organization for Research and Treatment of Cancer QLQ-C30: An examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30. European Journal Cancer Care (England), 13(2), 135–144. https://doi.org/10.1111/j.1365-2354.2003.00435.x.
Article
CAS
Google Scholar
MTRH Hospital (2019). http://www.mtrh.go.ke/. Accessed 22 Aug 2020.
Kobayashi, K., Takeda, F., Teramukai, S., Gotoh, I., Sakai, H., Yoneda, S., Noguchi, Y., Ogasawara, H., Yoshida, K. (1998). A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. European Journal of Cancer, 34(6), 810–815. https://doi.org/10.1016/s0959-8049(97)00395-x.
Kuenstner, S., Langelotz, C., Budach, V., Possinger, K., Krause, B., & Sezer, O. (2002). The comparability of quality of life scores. A multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. European Journal of Cancer, 38(3), 339–348. https://doi.org/10.1016/s0959-8049(01)00369-0.
Article
CAS
PubMed
Google Scholar
Luo, N., Fones, C. S., Lim, S. E., Xie, F., Thumboo, J., & Li, S. C. (2005). The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-c30): Validation of English version in Singapore. Quality of Life Research, 14(4), 1181–1186. https://doi.org/10.1007/s11136-004-4782-z.
Article
CAS
PubMed
Google Scholar
Mokkink, L. B., Terwee, C. B., Patrick, D. L., Alonso, J., Stratford, P. W., Knol, D. L., Bouter, L. M., de Vet, H. C. (2010). The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. Journal of Clinical Epidemiology, 63(7), 737–745. https://doi.org/10.1016/j.jclinepi.2010.02.006.
Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. McGraw-hill series in psychology, (3rd ed.) New York: McGraw-Hill.
Silpakit, C., Sirilerttrakul, S., Jirajarus, M., Sirisinha, T., Sirachainan, E., & Ratanatharathorn, V. (2006). The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30): Validation study of the Thai version. Quality of Life Research, 15(1), 167–172. https://doi.org/10.1007/s11136-005-0449-7.
Article
PubMed
Google Scholar
Sørensen, J. B., Klee, M., Palshof, T., & Hansen, H. H. (1993). Performance status assessment in cancer patients. An inter-observer variability study. British Journal of Cancer, 67(4), 773–775. https://doi.org/10.1038/bjc.1993.140.
Article
PubMed
PubMed Central
Google Scholar
Takeuchi, E. E., Keding, A., Awad, N., Hofmann, U., Campbell, L. J., Selby, P. J., Brown, J. M., Velikova, G. (2011). Impact of patient-reported outcomes in oncology: A longitudinal analysis of patient-physician communication. Journal of Clinical Oncology, 29(21), 2910–2917. https://doi.org/10.1200/JCO.2010.32.2453.
Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., & Selby, P. J. (2004). Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. Journal of Clinical Oncology, 22(4), 714–724. https://doi.org/10.1200/JCO.2004.06.078.
Article
PubMed
Google Scholar
Velikova, G., Keding, A., Harley, C., Cocks, K., Booth, L., Smith, A. B., Wright, P., Brown, J. M. (2010). Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: Secondary outcomes of a randomised controlled trial. European Journal of Cancer, 46(13), 2381–2388. https://doi.org/10.1016/j.ejca.2010.04.030.
Wambalaba, F. W., Son, B., Wambalaba, A. E., Nyong'o, D., & Nyong’o, A. (2019). Prevalence and capacity of cancer diagnostics and treatment: a demand and supply survey of health-care facilities in Kenya. Cancer Control, 26(1), 1073274819886930. https://doi.org/10.1177/1073274819886930.
Yun, Y. H., Park, Y. S., Lee, E. S., Bang, S. M., Heo, D. S., Park, S. Y., You, C. H., West, K. (2004). Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research, 13(4), 863–868. https://doi.org/10.1023/B:QURE.0000021692.81214.70.